Genmab A/S Stock Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
16:00:00 2026-08-13 EDT
|
5-day change | 1st Jan Change | ||
| 31.34 USD | -0.25% |
|
+7.11% | +1.75% |
| 08-12 | BNP Paribas Initiates Genmab at Outperform, With $40 Price Target | MT |
| 08-12 | Nordic stocks in North America: AstraZeneca fell 1.0% | FW |
| Market Cap | 121B 18.65B 16.16B 15.15B 13.83B 25.96B 1,779B 26.41B 178B 69.63B 892B 69.98B 68.48B 2,973B | P/E 2026 * |
25.7x | P/E 2027 * | 18.1x |
|---|---|---|---|---|---|
| Enterprise Value | 141B 21.67B 18.78B 17.61B 16.07B 30.17B 2,068B 30.69B 207B 80.93B 1,036B 81.34B 79.59B 3,456B | EV / Sales 2026 * |
4.84x | EV / Sales 2027 * | 3.92x |
| Free-Float |
95.41% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab A/S
| 1 day | -0.25% | ||
| 1 week | +7.11% | ||
| Current month | +8.56% | ||
| 1 month | +8.07% | ||
| 3 months | +15.69% | ||
| 6 months | +5.91% | ||
| Current year | +1.75% |
| 1 week | 30.52 |  | 31.79 |
| 1 month | 27.86 | | 31.79 |
| Current year | 23.62 | | 35.43 |
| 1 year | 22.48 | | 35.43 |
| 3 years | 17.24 | | 39.53 |
| 5 years | 17.24 | | 49.07 |
| 10 years | 12.1 | | 49.07 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2003-10-31 | |
| Director/Board Member | 58 | 2014-12-31 | |
| Director/Board Member | 75 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.25% | +7.11% | - | - | 18.77B | |
| +2.07% | +10.05% | +77.41% | +106.53% | 70.1B | |
| -0.87% | +0.77% | +36.57% | +65.91% | 54.93B | |
| -4.50% | +27.58% | +3.55% | +463.22% | 28.89B | |
| +0.04% | +12.56% | +54.67% | +5.47% | 23.9B | |
| -0.67% | -0.07% | -17.01% | -13.84% | 23.3B | |
| +0.35% | +8.24% | +252.94% | +466.50% | 18.41B | |
| -0.59% | +7.03% | +46.32% | -20.56% | 18.77B | |
| -0.57% | +6.85% | +30.20% | +580.70% | 16.1B | |
| +0.46% | -10.74% | +33.36% | +135.18% | 12.48B | |
| Average | -0.45% | +8.19% | +57.56% | +198.79% | 29.65B | |
| Weighted average by Cap. | -0.21% | +8.03% | +55.74% | +163.05% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 29.01B 4.47B 3.88B 3.64B 3.32B 6.23B 427B 6.34B 42.73B 16.71B 214B 16.79B 16.43B 713B | 33.71B 5.2B 4.51B 4.22B 3.86B 7.24B 496B 7.36B 49.65B 19.42B 249B 19.51B 19.09B 829B |
| Net income | 4.94B 762M 660M 619M 565M 1.06B 72.72B 1.08B 7.28B 2.85B 36.43B 2.86B 2.8B 122B | 7.17B 1.11B 959M 899M 821M 1.54B 106B 1.57B 10.56B 4.13B 52.9B 4.15B 4.06B 176B |
| Net Debt | 19.62B 3.03B 2.62B 2.46B 2.24B 4.21B 289B 4.29B 28.9B 11.3B 145B 11.36B 11.11B 483B | 11.13B 1.72B 1.49B 1.39B 1.27B 2.39B 164B 2.43B 16.39B 6.41B 82.07B 6.44B 6.3B 274B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-13 | US$31.34 | -0.25% | 4,094,649 |
| 26-08-12 | US$31.42 | +1.85% | 3,516,973 |
| 26-08-11 | US$30.85 | -0.06% | 1,587,051 |
| 26-08-10 | US$30.87 | -1.22% | 2,799,566 |
| 26-08-07 | US$31.25 | +4.76% | 3,507,362 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
